Fama 1996.

Methods	RCT. Active controlled.
Participants	36 people with OAG. Racial constitution is not reported. Inclusion criteria: unknown whether PEX or PDS were included, IOP above 23 mmHg without therapy, initial glaucomatous visual field defects, clinical signs of glaucomatous optic nerve damage. Exclusion criteria: active ocular infection or inflammation, acute or progressive retinal disorder, current use of systemic beta‐blocker.
Interventions	Timolol 0.5% twice daily. Betaxolol 0.5% twice daily. Carteolol 2% twice daily.
Outcomes	Change of visual field mean sensitivity. IOP. Corneal sensitivity. Tear production.
Notes	12 months follow up. No drop‐outs occurred. The authors do not state whether they analysed the mean sensitivities of both eyes of each patient.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear